Table 1: Phase III randomized, controlled trials investigating switch maintenance therapy.

Trial	Induction chemotherapy	Maintenance regimen	Median PFS	Median OS
GCOT, Westeel et al. JNCI 2005 [10]	Mitomycin + ifosfamide + cisplatin (MIC) × 4 cycles (or 2 cycles + radiation if stage IIIB)	Vinorelbine × 6 months vs. no further treatment	5 vs. 3 months, p = 0.11	12.3 vs. 12.3 months, p = 0.65
Sculier et al. Ann Oncol 2007 [11]	Gemcitabine + ifosfamide + cisplatin (GIP) × 3 cycles	Paclitaxel vs. GIP	4.0 vs. 4.4 months, p = 0.56	9.7 vs. 11.9 months, p = 0.17
JMEN, Ciuleanu et al. Lancet 2009 [12]	Platinum-based chemo × 4 cycles	Pemetrexed vs. placebo	4.3 vs. 2.6 months, P < 0.0001	13.4 vs. 10.6 months, p = 0.012
Fidias et al. JCO 2009 [13]	Carboplatin + gemcitabine × 4 cycles	Immediate vs. delayed docetaxel × maximum 6 cycles	5.7 vs. 2.7 months, p = 0.0001	12.3 vs. 9.7 months, p = 0.0853
SATURN, Cappuzzo et al. Lancet Oncol 2010 [14]	Platinum-based chemo × 4 cycles	Erlotinib vs. placebo	12.3 vs. 11.1 weeks, p < 0.0001	12.0 vs. 11.0 months, p = 0.0088
Perol et al. JCO 2012 [16]	Cisplatin + gemcitabine × 4 cycles	Erlotinibvs. observation (vs. gemcitabine)	2.9 vs. 1.9 months, p = 0.003	11.4 vs. 10.8 months, p = 0.3043
ATLAS, Johnson et al. JCO 2013 [15]	Chemotherapy + bevacizumab × 4 cycles	Bevacizumab + erlotinib vs. bevacizumab + placebo	4.8 vs. 3.7 months, p < 0.001	14.4 vs. 13.3 months, p = 0.5341